Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

Background Therapeutic strategies with immune checkpoint inhibitors (ICIs) counteract the immunosuppressive effects of programmed cell death protein-1 (PD-1) and ligand-1 (PD-L1). ICI treatment has emerged in first- and second-line therapy of non–small cell lung cancer (NSCLC). As immunotherapeutic...

Full description

Bibliographic Details
Main Authors: Gernot Wagner, Hannah Karolina Stollenwerk, Irma Klerings, Martin Pecherstorfer, Gerald Gartlehner, Josef Singer
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
immune checkpoint inhibitors
advanced non-small cell lung cancer
nsclc
systematic review
meta-analysis
pd-1
pd-l1
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1774314

Internet

http://dx.doi.org/10.1080/2162402X.2020.1774314

Similar Items